Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children’s Oncology Group (COG) Report

Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children’s Oncology Group (COG) Report. Clin Cancer Res. 2023 Apr 14;29(8):1546-1556. doi: 10.1158/1078-0432.CCR-22-3032. PubMed PMID: 36749880; PubMed Central PMCID: PMC10106446.

Patients ≥18 months of age with INSS Stage 3 unfavorable histology (UH), MYCN-non-amplified (MYCN-NA) tumors have favorable survival rates compared to other high-risk neuroblastoma populations. The impact of select clinical and biological factors on overall (OS) and event-free survival (EFS) were evaluated. Patients enrolled on COG A3973 (n=34), ANBL0532 (n=27), and/or biology protocol ANBL00B1 (n=72) were analyzed. Tumors with available DNA (n=65) and RNA (n=42) were subjected to whole exome sequencing (WES) and RNAseq. WES analyses and gene expression profiling were evaluated for their impact on survival. Multivariate analyses of EFS/OS using significant factors from univariate analyses were performed.